Kymera Eyes Alzheimer's Data by Year-End, Phase 3 Start in 2027
KYMR has more than doubled off its 52-week low of $36.65.
Summary
Kymera disclosed that topline data from the Phase 2b Alzheimer's trial of KT-621 is expected by year-end 2026, with plans to initiate Phase 3 by mid-2027. This follows the recent completion of enrollment in the atopic dermatitis trial and a Q2 report showing $65M in revenue and $1.5B in cash. The Alzheimer's readout is a major binary catalyst for a pipeline that has already attracted significant institutional selling. A positive outcome could transform the company's valuation, while failure would pressure the stock given the recent insider and fund liquidations.
At the time of this announcement, KYMR was trading at $105.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7B. The 52-week trading range was $36.65 to $130.05. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.